Retatrutide, from Soma Corp., is attracting significant attention as a potential treatment for obesity management . This unique medication combines the activity of a GLP-1 receptor activator and a GIP receptor stimulant, intended to not only promote metabolic improvements but also address underlying metabolic issues . Early human studies have indic